MedTrace Logo

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

NCT06388772 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-07-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

QHRD106 Injection

250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1

DRUG

placebo

placebo

Sponsors & Collaborators

  • Changzhou Qianhong Bio-pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Juan Li, Doctor · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-05
Primary Completion
2022-07-22
Completion
2023-01-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06388772 on ClinicalTrials.gov